Martinez-Useros, Javier <br/><br/>
DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.  [electronic resource] 

 -  BMC cancer  Dec 2014 
 - 965 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1471-2407 
<br/><br/><label>Standard No.: </label>10.1186/1471-2407-14-965  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Agents, Phytogenic--therapeutic use<br/>Apoptosis<br/>Biomarkers, Tumor--analysis<br/>Camptothecin--analogs & derivatives<br/>Cell Line, Tumor<br/>Cell Movement<br/>Cell Survival<br/>Chromosomal Proteins, Non-Histone--analysis<br/>Colorectal Neoplasms--chemistry<br/>Down-Regulation<br/>Female<br/>Gene Expression<br/>Gene Knockdown Techniques<br/>Humans<br/>Irinotecan<br/>Male<br/>Middle Aged<br/>Oncogene Proteins--analysis<br/>Phenotype<br/>Poly-ADP-Ribose Binding Proteins<br/>Proto-Oncogene Proteins--genetics<br/>Proto-Oncogene Proteins p21(ras)<br/>ras Proteins--genetics